Clinical Trials
3 trialsNCT02709889 2020-10-19
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie
Phase 1/2 Terminated
NCT04001725 2019-11-13
OPTIMAL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT02862145 2016-09-27
MRX34-102
Mirna Therapeutics, Inc.
Phase 1/2 Withdrawn